Glycosylated enfuvirtide: A long-lasting glycopeptide with potent anti-HIV activity

Journal of Medicinal Chemistry

Volumn 58, Issue 3, 2015, Pages 1372-1379

  Cheng, Shuihong ^a,b   Chang, Xuesong ^a   Wang, Yan ^c   Gao, George F ^a,d   Shao, Yiming ^c   Ma, Liying ^c   Li, Xuebing ^a,b,d  

^a INSTITUTE OF MICROBIOLOGY   (China)

^b JIANGXI NORMAL UNIVERSITY   (China)

^c CHINESE CENTER FOR DISEASE CONTROL AND PREVENTION   (China)

^d INSTITUTE OF GEOLOGY AND GEOPHYSICS   (China)

Author keywords

[No Author keywords available]

Indexed keywords

2 AZIDOETHYL O (5 ACETAMIDO 3,5 DIDEOXY DEXTRO GLYCERO ALPHA DEXTRO GALACTO 2 NONULOPYRANOSYLICACID) (2-6) O BETA DEXTRO GALACTOPYRANOSYL (1-4) O BETA DEXTRO GLUCOPYRANOSIDE; ENFUVIRTIDE; N [2 [2 [2 (2 PROPYNYLOXY)ETHOXY]ETHOXY]ETHYL]MALEIMIDE; N [2 [2 [2 [[1 (BETA DEXTRO GALACTOPYRANOSYL (1-4) O BETA DEXTRO GLUCOPYRANOSYLOXYETHYL) 1H 1,2,3 TRIAZOL 4 YL]METHOXY]ETHOXY]ETHOXY]ETHYL]MALEIMIDE; N [2 [2 [2 [[1 [O (5 ACETAMIDO 3,5 DIDEOXY DEXTRO GLYCERO ALPHA DEXTRO GALACTO 2 NONULOPYRANOSYLONIC ACID) (2-6) O BETA DEXTRO GALACTOPYRANOSYL (1-4) BTEA DEXTRO GLUCOPYRANOSYLOXYETHYL) 1H 1,2,3 TRIAZOL 4 YL]METHOXY]ETHOXY]ETHOXY]ETHYL]MALEIMIDE; SIALIC ACID; UNCLASSIFIED DRUG; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; GLYCOPEPTIDE; GLYCOPROTEIN GP 41; PEPTIDE FRAGMENT;

ALPHA HELIX; ANIMAL EXPERIMENT; ANTIVIRAL ACTIVITY; ARTICLE; CELL VIABILITY; CIRCULAR DICHROISM; CYCLOADDITION; DENATURATION; DRUG BINDING; DRUG CLEARANCE; DRUG CONFORMATION; DRUG HALF LIFE; DRUG MECHANISM; DRUG POTENCY; DRUG SOLUBILITY; DRUG SYNTHESIS; GLYCOSYLATION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; LIVER CLEARANCE; LONG TERMINAL REPEAT; MALE; MASS SPECTROMETRY; NONHUMAN; PROTEIN SECONDARY STRUCTURE; PROTEIN STRUCTURE; RAT; SIALYLATION; SINGLE DRUG DOSE; STEREOSPECIFICITY; SURFACE PLASMON RESONANCE; VIRUS ENTRY; XTT ASSAY; CHEMICAL STRUCTURE; CHEMISTRY; DOSE RESPONSE; DRUG EFFECTS; HUMAN IMMUNODEFICIENCY VIRUS; MICROBIAL SENSITIVITY TEST; STRUCTURE ACTIVITY RELATION; SYNTHESIS;

ANTI-HIV AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; GLYCOPEPTIDES; GLYCOSYLATION; HIV; HIV ENVELOPE PROTEIN GP41; MICROBIAL SENSITIVITY TESTS; MOLECULAR STRUCTURE; PEPTIDE FRAGMENTS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84922767939     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm5016582     Document Type: Article

References (52)

1. Dwek, R. A. Glycobiology: toward understanding the function of sugars Chem. Rev. 1996, 96, 683-720
2. Solá, R. J.; Griebenow, K. Glycosylation of therapeutic proteins: an effective strategy to optimize efficacy BioDrugs 2010, 24, 9-21
3. Morell, A. G.; Gregoriadis, G.; Scheinberg, I. H.; Hickman, J.; Ashwell, G. The role of sialic acid in determining the survival of glycoproteins in the circulation J. Biol. Chem. 1971, 246, 1461-1467
4. Elliott, S.; Egrie, J.; Browne, J.; Lorenzini, T.; Busse, L.; Rogers, N.; Ponting, I. Control of rHuEPO biological activity: The role of carbohydrate Exp. Hematol. 2004, 32, 1146-1155
5. Byrne, B.; Donohoe, G. G.; O'Kennedy, R. Sialic acids: carbohydrate moieties that influence the biological and physical properties of biopharmaceutical proteins and living cells Drug Discovery Today 2007, 12, 319-326
6. Bork, K.; Horstkorte, R.; Weidemann, W. Increasing the sialylation of therapeutic glycoproteins: The potential of the sialic acid biosynthetic pathway J. Pharm. Sci. 2009, 98, 3499-3508
7. Veronese, F. M.; Pasut, G. PEGylation, successful approach to drug delivery Drug Discovery Today 2005, 10, 1451-1458
8. Pisal, D. S.; Kosloski, M. P.; Balu-Iyer, S. V. Delivery of therapeutic proteins J. Pharm. Sci. 2010, 99, 2557-2575
9. Elliott, S.; Lorenzini, T.; Asher, S.; Aoki, K.; Brankow, D.; Buck, L.; Busse, L.; Chang, D.; Fuller, J.; Grant, J.; Hernday, N.; Hokum, M.; Hu, S.; Knudten, A.; Levin, N.; Komorowski, R.; Martin, F.; Navarro, R.; Osslund, T.; Rogers, G.; Rogers, N.; Trail, G.; Egrie, J. Enhancement of therapeutic protein in vivo activities through glycoengineering Nat. Biotechnol. 2003, 21, 414-421
10. Sethuraman, N.; Stadheim, T. A. Challenges in therapeutic glycoprotein production Curr. Opin. Biotechnol. 2006, 17, 341-346
11. Gamblin, D. P.; Scanlan, E. M.; Davis, B. G. Glycoprotein synthesis: An update Chem. Rev. 2009, 109, 131-163
12. Buskas, T.; Ingale, S.; Boons, G.-J. Glycopeptides as versatile tools for glycobiology Glycobiology 2006, 16, 113R-136R
13. Kihlberg, J.; Ahman, J.; Walse, B.; Drakenberg, T.; Nilsson, A.; Söderberg-ahlm, C.; Bengtsson, B.; Olsson, H. Glycosylated peptide hormones: pharmacological properties and conformational studies of analogues of [1-desamino,8- d -arginine]vasopressin J. Med. Chem. 1995, 38, 161-169
14. Ueda, T.; Tomita, K.; Notsu, Y.; Ito, T.; Fumoto, M.; Takakura, T.; Nagatome, H.; Takimoto, A.; Mihara, S.; Togame, H.; Kawamoto, K.; Iwasaki, T.; Asakura, K.; Oshima, T.; Hanasaki, K.; Nishimura, S.; Kondo, H. Chemoenzymatic synthesis of glycosylated glucagon-like peptide 1: Effect of glycosylation on proteolytic resistance and in vivo blood glucose-lowering activity J. Am. Chem. Soc. 2009, 131, 6237-6245
15. Styslinger, T. J.; Zhang, N.; Bhatt, V. S.; Pettit, N.; Palmer, A. F.; Wang, P. G. Site-selective glycosylation of hemoglobin with variable molecular weight oligosaccharides: Potential alternative to PEGylation J. Am. Chem. Soc. 2012, 134, 7507-7515
16. Sato, M.; Sadamoto, R.; Niikura, K.; Monde, K.; Kondo, H.; Nishimura, S. I. Site-specific introduction of sialic acid into insulin Angew. Chem., Int. Ed. 2004, 43, 1516-1520
17. Sato, M.; Furuike, T.; Sadamoto, R.; Fujitani, N.; Nakahara, T.; Niikura, K.; Monde, K.; Kondo, H.; Nishimura, S. Glycoinsulins: Dendritic sialyloligosaccharide-displaying insulins showing a prolonged blood-sugar-lowering activity J. Am. Chem. Soc. 2004, 126, 14013-14022
18. Van Kasteren, S. I.; Kramer, H. B.; Jensen, H. H.; Campbell, S. J.; Kirkpatrick, J.; Oldham, N. J.; Anthony, D. C.; Davis, B. G. Expanding the diversity of chemical protein modification allows post-translational mimicry Nature 2007, 446, 1105-1109
19. Matthews, T.; Salgo, M.; Greenberg, M.; Chung, J.; DeMasi, R.; Bolognesi, D. Enfuvirtide: The first therapy to inhibit the entry of HIV-1 into host CD4 lymphocytes Nat. Rev. Drug Discovery 2004, 3, 215-225
20. Teicher, E.; Abbara, C.; Duclos-Vallée, J. C.; Antonini, T.; Bonhomme-Faivre, L.; Desbois, D.; Samuel, D.; Vittecoq, D. Enfuvirtide: A safe and effective antiretroviral agent for human immunodeficiency virus-infected patients shortly after liver transplantation Liver Transplant. 2009, 15, 1336-1342
21. Mirza, R.; Turiansky, G. Enfuvirtide and cutaneous injection-site reactions J. Drugs Dermatol. 2012, 11, e35-e38
22. Naider, F.; Anglister, J. Peptides in the treatment of AIDS Curr. Opin. Struct. Biol. 2009, 19, 473-482
23. Danial, M.; Van Dulmen, T. H.; Aleksandrowicz, J.; Pötgens, A. J.; Klok, H.-A. Site-specific PEGylation of HR2 peptides: Effects of PEG conjugation position and chain length on HIV-1 membrane fusion inhibition and proteolytic degradation Bioconjugate Chem. 2012, 23, 1648-1660
24. Ingallinella, P.; Bianchi, E.; Ladwa, N. A.; Wang, Y.-J.; Hrin, R.; Veneziano, M.; Bonelli, F.; Ketas, T. J.; Moore, J. P.; Miller, M. D.; Pessi, A. Addition of a cholesterol group to an HIV-1 peptide fusion inhibitor dramatically increases its antiviral potency Proc. Natl. Acad. Sci. U. S. A. 2009, 106, 5801-5806
25. Stoddart, C. A.; Nault, G.; Galkina, S.; Thibaudeau, A. K.; Bakis, P.; Bousquet-Gagnon, N.; Robitaille, M.; Bellomo, M.; Paradis, V.; Liscourt, P.; Lobach, A.; Rivard, M.-E.; Ptak, R. G.; Mankowski, M. K.; Bridon, D.; Quraishi, O. Albumin-conjugated C34 peptide HIV-1 fusion inhibitor: equipotent to C34 and T-20 in vitro with sustained activity in SCID-hu Thy/Liv mice J. Biol. Chem. 2008, 283, 34045-34052
26. Xiao, J.; Burn, A.; Tolbert, T. J. Increasing solubility of proteins and peptides by site-specific modification with betaine Bioconjugate Chem. 2008, 19, 1113-1118
27. Huet, T.; Kerbarh, O.; Schols, D.; Clayette, P.; Gauchet, C.; Dubreucq, G.; Vincent, L.; Bompais, H.; Mazinghien, R.; Querolle, O.; Salvador, A.; Lemoine, J.; Lucidi, B.; Balzarini, J.; Petitou, M. Long-lasting enfuvirtide carrier pentasaccharide conjugates with potent anti-human immunodeficiency virus type 1 activity Antimicrob. Agents Chemother. 2010, 54, 134-142
28. He, Y.; Xiao, Y.; Song, H.; Liang, Q.; Ju, D.; Chen, X.; Lu, H.; Jing, W.; Jiang, S.; Zhang, L. Design and evaluation of sifuvirtide, a novel HIV-1 fusion inhibitor J. Biol. Chem. 2008, 283, 11126-11134
29. Chang, C.-H.; Hinkula, J.; Loo, M.; Falkeborn, T.; Li, R.; Cardillo, T. M.; Rossi, E. A.; Goldenberg, D. M.; Wahren, B. A novel class of anti-HIV agents with multiple copies of enfuvirtide enhances inhibition of viral replication and cellular transmission in vitro PloS One 2012, 7, e41235
30. Ding, S.; Song, M.; Sim, B.-C.; Gu, C.; Podust, V. N.; Wang, C.-W.; McLaughlin, B.; Shah, T. P.; Lax, R.; Gast, R.; Sharan, R.; Vaseck, A.; Hartman, M. A.; Deniston, C.; Srinivas, P.; Schellenberger, V. Multivalent antiviral XTEN-peptide conjugates with long in vivo half-life and enhanced solubility Bioconjugate Chem. 2014, 25, 1351-1359
31. Naicker, K. P.; Li, H.; Heredia, A.; Song, H.; Wang, L. X. Design and synthesis of αGal-conjugated peptide T20 as novel antiviral agent for HIV-immunotargeting Org. Biomol. Chem. 2004, 2, 660-664
32. Ni, J.; Singh, S.; Wang, L. X. Synthesis of maleimide-activated carbohydrates as chemoselective tags for site-specific glycosylation of peptides and proteins Bioconjugate Chem. 2003, 14, 232-238
33. Wang, L. X.; Song, H.; Liu, S.; Lu, H.; Jiang, S.; Ni, J.; Li, H. Chemoenzymatic synthesis of HIV-1 gp41 glycopeptides: Effects of glycosylation on the anti-HIV activity and α-helix bundle-forming ability of peptide C34 ChemBioChem. 2005, 6, 1068-1074
34. Huang, W.; Groothuys, S.; Heredia, A.; Kuijper, B. H.; Rutjes, F. P.; van Delft, F. L.; Wang, L. X. Enzymatic glycosylation of triazole-linked GlcNAc/Glc-peptides: Synthesis, stability and anti-HIV activity of triazole-linked HIV-1 gp41 glycopeptide C34 analogues ChemBioChem. 2009, 10, 1234-1242
35. Kitagawa, T.; Aikawa, T. Enzyme coupled immunoassay of insulin using a novel coupling reagent J. Biochem. 1976, 79, 233-236
36. Chernyak, A.; Oscarson, S.; Turek, D. Synthesis of the Lewis b hexasaccharide and squarate acid-HSA conjugates thereof with various saccharide loadings Carbohydr. Res. 2000, 329, 309-316
37. Fazio, F.; Bryan, M. C.; Blixt, O.; Paulson, J. C.; Wong, C. H. Synthesis of sugar arrays in microtiter plate J. Am. Chem. Soc. 2002, 124, 14397-14402
38. Rostovtsev, V. V.; Green, L. G.; Fokin, V. V.; Sharpless, K. B. A stepwise Huisgen cycloaddition process: Copper(I)-catalyzed regioselective "ligation" of azides and terminal alkynes Angew. Chem., Int. Ed. 2002, 114, 2596-2599
39. Natarajan, A.; Du, W.; Xiong, C. Y.; DeNardo, G. L.; DeNardo, S. J.; Gervay-Hague, J. Construction of di-scFv through a trivalent alkyne-axide 1,3-dipolar cycloaddition Chem. Commun. 2007, 695-697
40. Wei, X.; Decker, J. M.; Wang, S.; Hui, H.; Kappes, J. C.; Wu, X.; Salazar-Gonzalez, J. F.; Salazar, M. G.; Kilby, J. M.; Saag, M. S.; Komarova, N. L.; Nowak, M. A.; Hahn, B. H.; Kwong, P. D.; Shaw, G. M. Antibody neutralization and escape by HIV-1 Nature 2003, 422, 307-312
41. Huang, Y.; Wang, X.; Yu, X.; Yuan, L.; Guo, Y.; Xu, W.; Liu, T.; Liu, J.; Shao, Y.; Ma, L. Inhibitory activity of 9-phenylcyclohepta[ d ]pyrimidinedione derivatives against different strains of HIV-1 as non-nucleoside reverse transcriptase inhibitors Virol. J. 2011, 8, 230
42. Liu, S.; Jing, W.; Cheung, B.; Lu, H.; Sun, J.; Yan, X.; Niu, J.; Farmar, J.; Wu, S.; Jiang, S. HIV gp41 C-terminal heptad repeat contains multifunctional domains: Relation to mechanisms of action of anti-HIV peptides J. Biol. Chem. 2007, 282, 9612-9620
43. Lawless, M. K.; Barney, S.; Guthrie, K. I.; Bucy, T. B.; Petteway, S. R.; Merutka, G. HIV-1 membrane fusion mechanism: Structural studies of the interactions between biologically-active peptides from gp41 Biochemistry 1996, 35, 13697-13708
44. Peisajovich, S. G.; Gallo, S. A.; Blumenthal, R.; Shai, Y. C-Terminal octylation rescues an inactive T20 mutant: Implications for the mechanism of HIV/SIMIAN immunodeficiency virus-induced membrane fusion J. Biol. Chem. 2003, 278, 21012-21017
45. Qi, Z.; Shi, W.; Xue, N.; Pan, C.; Jing, W.; Liu, K.; Jiang, S. Rationally designed anti-HIV peptides containing multifunctional domains as molecule probes for studying the mechanisms of action of the first and second generation HIV fusion inhibitors J. Biol. Chem. 2008, 283, 30376-30384
46. O'Connor, S. E.; Imperiali, B. A molecular basis for glycosylation-induced conformational switching Chem. Biol. 1998, 5, 427-437
47. Hanson, S. R.; Culyba, E. K.; Hsu, T.-L.; Wong, C.-H.; Kelly, J. W.; Powers, E. T. The core trisaccharide of an N-linked glycoprotein intrinsically accelerates folding and enhances stability Proc. Natl. Acad. Sci. U. S. A. 2009, 106, 3131-3136
48. Laughrey, Z. R.; Kiehna, S. E.; Riemen, A. J.; Waters, M. L. Carbohydrate-π interactions: What are they worth? J. Am. Chem. Soc. 2008, 130, 14625-14633
49. Chan, D. C.; Fass, D.; Berger, J. M.; Kim, P. S. Core structure of gp41 from the HIV envelope glycoprotein Cell 1997, 89, 263-273
50. Lin, H. S.; Yue, B. D.; Ho, P. C. Determination of pterostilbene in rat plasma by a simple HPLC-UV method and its application in pre-clinical pharmacokinetic study Biomed. Chromatogr. 2009, 23, 1308-1315
51. Rodríguez-Gutiérrez, G.; Wood, S.; Fernández-Bolaños Guzmán, J.; Duthie, G. G.; De Roos, B. Determination of 3,4-dihydroxyphenylglycol, hydroxytyrosol and tyrosol purified from olive oil by-products with HPLC in animal plasma and tissues Food Chem. 2011, 126, 1948-1952
52. Jiang, S.; Lu, H.; Liu, S.; Zhao, Q.; He, Y.; Debnath, A. K. N-Substituted pyrrole dericatives as novel human immunodeficiency virus type 1 entry inhibitors that interfere with the gp41 six-helix bundle formation and block virus fusion Antimicrob. Agents Chemother. 2004, 48, 4349-4359